PortfoliosLab logoPortfoliosLab logo
BBIO vs. XLK
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BBIO vs. XLK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and State Street Technology Select Sector SPDR ETF (XLK). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BBIO achieves a -8.89% return, which is significantly lower than XLK's 28.51% return.


BBIO

1D
0.48%
1M
2.89%
YTD
-8.89%
6M
-8.94%
1Y
57.03%
3Y*
65.08%
5Y*
2.89%
10Y*

XLK

1D
0.83%
1M
-0.19%
YTD
28.51%
6M
26.47%
1Y
48.82%
3Y*
31.01%
5Y*
21.42%
10Y*
25.76%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BBIO vs. XLK - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
BBIO
BridgeBio Pharma, Inc.
-8.89%178.75%-32.03%429.79%-54.32%-76.54%102.88%14.51%
XLK
State Street Technology Select Sector SPDR ETF
28.51%24.61%21.63%56.02%-27.73%34.74%43.62%18.50%

Correlation

The correlation between BBIO and XLK is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.29

Correlation (5Y)
Calculated over the trailing 5-year period

0.33

Correlation (All Time)
Calculated using the full available price history since Jun 27, 2019

0.32

The correlation between BBIO and XLK shifts across timeframes, from 0.23 (1 year) to 0.33 (5 years), reflecting how their relationship changes across market environments.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BBIO vs. XLK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBIO
BBIO Risk / Return Rank: 7979
Overall Rank
BBIO Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
BBIO Sortino Ratio Rank: 7676
Sortino Ratio Rank
BBIO Omega Ratio Rank: 7777
Omega Ratio Rank
BBIO Calmar Ratio Rank: 8383
Calmar Ratio Rank
BBIO Martin Ratio Rank: 8282
Martin Ratio Rank

XLK
XLK Risk / Return Rank: 6969
Overall Rank
XLK Sharpe Ratio Rank: 7676
Sharpe Ratio Rank
XLK Sortino Ratio Rank: 6666
Sortino Ratio Rank
XLK Omega Ratio Rank: 6969
Omega Ratio Rank
XLK Calmar Ratio Rank: 7171
Calmar Ratio Rank
XLK Martin Ratio Rank: 6262
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBIO vs. XLK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and State Street Technology Select Sector SPDR ETF (XLK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BBIOXLKDifference
Sharpe ratioReturn per unit of total volatility

-0.85

Sortino ratioReturn per unit of downside risk

-0.72

Omega ratioGain probability vs. loss probability

1.25

1.35

-0.10

Calmar ratioReturn relative to maximum drawdown

2.83

3.08

-0.25

Martin ratioReturn relative to average drawdown

6.56

9.75

-3.19

BBIO vs. XLK - Sharpe Ratio Comparison

The current BBIO Sharpe Ratio is 1.24, which is lower than the XLK Sharpe Ratio of 2.09. The chart below compares the historical Sharpe Ratios of BBIO and XLK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BBIO vs. XLK - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, which is greater than XLK's maximum drawdown of -82.05%. Use the drawdown chart below to compare losses from any high point for BBIO and XLK.


Loading charts...

Drawdown Indicators


BBIOXLKDifference

Max Drawdown

Largest peak-to-trough decline

-92.80%

-82.05%

-10.75%

Max Drawdown (1Y)

Largest decline over 1 year

-20.25%

-15.92%

-4.33%

Max Drawdown (3Y)

Largest decline over 3 years

-49.08%

-25.66%

-23.42%

Max Drawdown (5Y)

Largest decline over 5 years

-91.89%

-33.56%

-58.33%

Max Drawdown (10Y)

Largest decline over 10 years

-33.56%

Current Drawdown

Current decline from peak

-12.79%

-6.77%

-6.02%

Average Drawdown

Average peak-to-trough decline

-45.63%

-34.89%

-10.74%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.72%

5.02%

+3.70%

Volatility

BBIO vs. XLK - Volatility Comparison

The current volatility for BridgeBio Pharma, Inc. (BBIO) is 8.81%, while State Street Technology Select Sector SPDR ETF (XLK) has a volatility of 12.25%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than XLK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BBIOXLKDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.81%

12.25%

-3.44%

Volatility (6M)

Calculated over the trailing 6-month period

34.25%

19.63%

+14.62%

Volatility (1Y)

Calculated over the trailing 1-year period

46.12%

23.42%

+22.70%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

85.95%

25.37%

+60.58%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.60%

24.71%

+58.89%

Dividends

BBIO vs. XLK - Dividend Comparison

BBIO has not paid dividends to shareholders, while XLK's dividend yield for the trailing twelve months is around 0.43%.


PositionTTM20252024202320222021202020192018201720162015
BBIO
BridgeBio Pharma, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
XLK
State Street Technology Select Sector SPDR ETF
0.43%0.54%0.66%0.76%1.04%0.65%0.92%1.16%1.60%1.37%1.74%1.79%

Frequently Asked Questions


BBIO and XLK have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

XLK has higher volatility (12.25%) compared to BBIO (8.81%). In terms of maximum drawdown, BBIO dropped -92.80% vs XLK's -82.05%.

XLK currently has the higher Sharpe Ratio (2.09 vs 1.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BBIO and XLK

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer